Abstract
Background Sleep apnoea (SA) and type 2 diabetes (T2D) have been linked to malignancy. The aim of the present study was to evaluate the association between SA and incidence of malignancy in patients with T2D.
Methods The DIACORE (DIAbetes COhoRtE) study is a prospective, population-based cohort study in T2D patients. In the SDB (sleep-disordered breathing) sub-study, the apnoea-hypopnoea index (AHI), oxygen desaturation index (ODI) and percentage of night-time spent below a peripheral oxygen saturation of 90% (TSat90%) were assessed using a two-channel ambulatory monitoring device. Malignancy diagnoses were gathered using self-reported medical history data validated by medical records. Hazard ratios (HR) for incident malignancy were derived by Cox regression adjusting for sex, age, body-mass index, smoking status, alcohol intake, socioeconomic status and HbA1c.
Results Of 1239 patients with T2D (mean age 67 years, 41% female, mean body-mass index 30.9 kg m−2), 79 (6.4%) were first-time diagnosed with a malignancy within a median follow-up period of 2.7 (interquartile range 2.2; 4.5) years. AHI, ODI and TSat90% were not associated with incident malignancy. In subgroup analysis, women showed increased cancer risk per AHI unit (adjusted HR 1.03 per AHI unit, 95% CI [1.00–1.06], p=0.028) and severe SA (defined as AHI≥30 h−1; adjusted HR 4.19, 95% CI [1.39–12.77], p=0.012). This was not seen in men, and a significant interaction was observed (interaction terms, p=0.048, p=0.033, respectively).
Conclusion SA was not associated with incident malignancy in T2D patients. However, stratified analysis revealed a significant association between SA and incident malignancy in women, but not in men.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Dr. Driendl has nothing to disclose.
Dr. Arzt reports grants from Else-Kröner Fresenius Foundation, grants from Resmed Foundation, grants and personal fees from Philips Respironics, grants and personal fees from ResMed, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Brestotec, personal fees from NRI, outside the submitted work.
Dr. Zimmermann has nothing to disclose.
Dr. Jung has nothing to disclose.
Dr. Pukrop has nothing to disclose.
Dr. Böger reports grants from KfH Stiftung Präventivmedizin e.V., grants from Else Kröner-Fresenius-Stiftung, grants from Dr. Robert Pfleger Stuftung, during the conduct of the study.
Dr. Haferkamp has nothing to disclose.
Mr. Zeman has nothing to disclose.
Dr. Heid has nothing to disclose.
Dr. Stadler has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received January 17, 2021.
- Accepted February 6, 2021.
- Copyright ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
